Sanofi’s Rilzabrutinib Receives Orphan De...
Sanofi's rilzabrutinib has received orphan drug designation from the European Medicines Agency for treating IgG4-related disease (IgG4-RD). This reversible covalent Bruton's tyrosine kinase (BTK) inhibitor earned the designation based on promising...